Literature DB >> 24361467

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

Yi Ni1, Florian A Lempp1, Stefan Mehrle1, Shirin Nkongolo1, Christina Kaufman1, Maria Fälth2, Jan Stindt3, Christian Königer4, Michael Nassal4, Ralf Kubitz3, Holger Sültmann2, Stephan Urban5.   

Abstract

BACKGROUND & AIMS: Hepatitis B and D viruses (HBV and HDV) are human pathogens with restricted host ranges and high selectivity for hepatocytes; the HBV L-envelope protein interacts specifically with a receptor on these cells. We aimed to identify this receptor and analyze whether it is the recently described sodium-taurocholate co-transporter polypeptide (NTCP), encoded by the SLC10A1 gene.
METHODS: To identify receptor candidates, we compared gene expression patterns between differentiated HepaRG cells, which express the receptor, and naïve cells, which do not. Receptor candidates were evaluated by small hairpin RNA silencing in HepaRG cells; the ability of receptor expression to confer binding and infection were tested in transduced hepatoma cell lines. We used interspecies domain swapping to identify motifs for receptor-mediated host discrimination of HBV and HDV binding and infection.
RESULTS: Bioinformatic analyses of comparative expression arrays confirmed that NTCP, which was previously identified through a biochemical approach is a bona fide receptor for HBV and HDV. NTCPs from rat, mouse, and human bound Myrcludex B, a peptide ligand derived from the HBV L-protein. Myrcludex B blocked NTCP transport of bile salts; small hairpin RNA-mediated knockdown of NTCP in HepaRG cells prevented their infection by HBV or HDV. Expression of human but not mouse NTCP in HepG2 and HuH7 cells conferred a limited cell-type-related and virus-dependent susceptibility to infection; these limitations were overcome when cells were cultured with dimethyl sulfoxide. We identified 2 short-sequence motifs in human NTCP that were required for species-specific binding and infection by HBV and HDV.
CONCLUSIONS: Human NTCP is a specific receptor for HBV and HDV. NTCP-expressing cell lines can be efficiently infected with these viruses, and might be used in basic research and high-throughput screening studies. Mapping of motifs in NTCPs have increased our understanding of the species specificities of HBV and HDV, and could lead to small animal models for studies of viral infection and replication.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Myrcludex B; Species Specificity; Virology; Virus Entry

Mesh:

Substances:

Year:  2013        PMID: 24361467     DOI: 10.1053/j.gastro.2013.12.024

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  274 in total

Review 1.  Hepatitis delta virus: A fascinating and neglected pathogen.

Authors:  Celso Cunha; João Paulo Tavanez; Severin Gudima
Journal:  World J Virol       Date:  2015-11-12

Review 2.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

Review 3.  Future therapy for hepatitis B virus infection.

Authors:  Masahito Minami
Journal:  Clin J Gastroenterol       Date:  2015-08-12

Review 4.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors:  Ju-Tao Guo; Haitao Guo
Journal:  Antiviral Res       Date:  2015-08-10       Impact factor: 5.970

Review 5.  Antiviral therapies and prospects for a cure of chronic hepatitis B.

Authors:  Fabien Zoulim; David Durantel
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

6.  Activation of Stimulator of Interferon Genes in Hepatocytes Suppresses the Replication of Hepatitis B Virus.

Authors:  Fang Guo; Liudi Tang; Sainan Shu; Mohit Sehgal; Muhammad Sheraz; Bowei Liu; Qiong Zhao; Junjun Cheng; Xuesen Zhao; Tianlun Zhou; Jinhong Chang; Ju-Tao Guo
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

7.  Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.

Authors:  Benjamin Y Winer; Elham Shirvani-Dastgerdi; Yaron Bram; Julie Sellau; Benjamin E Low; Heath Johnson; Tiffany Huang; Gabriela Hrebikova; Brigitte Heller; Yael Sharon; Katja Giersch; Sherif Gerges; Kathleen Seneca; Mihai-Alexandru Pais; Angela S Frankel; Luis Chiriboga; John Cullen; Ronald G Nahass; Marc Lutgehetmann; Jared E Toettcher; Michael V Wiles; Robert E Schwartz; Alexander Ploss
Journal:  Sci Transl Med       Date:  2018-06-27       Impact factor: 17.956

8.  The Na(+) -taurocholate cotransporting polypeptide knockout mouse: A new tool for study of bile acids and hepatitis B virus biology.

Authors:  Astrid Kosters; Paul A Dawson
Journal:  Hepatology       Date:  2015-04-08       Impact factor: 17.425

9.  The Loss-of-Function S267F Variant in HBV Receptor NTCP Reduces Human Risk for HBV Infection and Disease Progression.

Authors:  Ping An; Zheng Zeng; Cheryl A Winkler
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

Review 10.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.